Advanced Search | Help

Newsroom

Events and Conferences
February 2010
SMTWTFS
123456
78910111213
14151617181920
21222324252627
28


Statistics
SAMHSA News Room
Contact Media Services: (240) 276-2130

SAMHSA News Bulletin

Date: 5/4/2007
Media Contact: SAMHSA Press Office
Telephone: 240-276-2130

Comparison of Extended-Release and Oral Naltrexone Assists Substance Abuse Treatment Providers

Oral naltrexone and naltrexone for extended-release injectable suspension are the focus of a new comparative report recently released by the Substance Abuse and Mental Health Services Administration (SAMHSA) in the Spring 2007 issue of Substance Abuse Treatment Advisory.  
 
 In April 2006, the U.S. Food and Drug Administration approved a new extended-release injectable formulation of naltrexone (Vivitrol®) for the treatment of alcohol dependence in an effort to address the issue of patient non-adherence to oral treatment.

 This issue of the Substance Abuse Treatment Advisory compares oral naltrexone and extended release injectable naltrexone. It also answers questions treatment providers, particularly counselors and program administrators, may have about injectable naltrexone. These questions include—

  • What is naltrexone for extended-release injectable suspension?
  • How does injectable naltrexone address patient non-adherence?
  • What is the efficacy of injectable naltrexone?
  • How safe is injectable naltrexone?
  • How can substance abuse specialty treatment providers incorporate injectable naltrexone into their practice?

 The comparison table offers seven topical comparisons in the following categories: mechanism of action, usual adult dosage and prescribing information, examples of drugs causing interactions, common side effects, contraindications, precautions and serious adverse reactions.   In addition, the report provides information that treatment providers should share with the patients about the drug as well as the effectiveness of injectable naltrexone.

 “Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence” (Substance Abuse Treatment Advisory, Spring 2007, Volume 6, Issue 1) is available on the Web at http://www.kap.samhsa.gov/products/manuals/advisory/index.htm. Copies may be obtained free of charge by calling SAMHSA’s Health Information Network at 1-877-SAMHSA-7 (1-877-726-4727). Request inventory number SMA 07-4267. For related publications and information, visit http://www.samhsa.gov/.

SAMHSA is a public health agency within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity and effectiveness of the nation's substance abuse prevention, addictions treatment, and mental health services delivery system.


Page Last Updated: 5/3/2007